A Phase 4 interventional study of Ambulatory phlebectomy and Foam sclerotherapy in Varicose Veins, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-05.
Sponsored by Imperial College London · Phase 4, Interventional, and Treatment
Among 10 studies in Varicose Veins by Imperial College London — 2 open to participants now, 2 under way, none of them phase 3. Varicose Veins · Imperial College London.
Among the 10 studies in Varicose Veins by Imperial College London, this one is the only one that started in 2018, is one of 2 in phase 4, and was the 6th registered.
226 studies on the registry are indexed under Varicose Veins; 30 are open to participants now.
Browse Varicose Veins studies →2 of the 10 studies in Varicose Veins by Imperial College London are open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
By country, each count listing its studies:
Of the 22 Varicose Veins studies recruiting now, 12 (55%) set no upper age limit and 4 (18%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2018.
This study's planned enrollment of 160 is above the median of 101 across 154 interventional studies indexed under Varicose Veins.
Median enrollment 164 across the 8 interventional studies, 75 across the 2 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 843 studies on the registry; 180 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
1 of the studies in Varicose Veins by Imperial College London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05735639Imperial College LondonTHRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) | 2027-06-30 |
Among the 10 studies in Varicose Veins by Imperial College London, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be comparing the treatment of varicose vein tributaries using either foam sclerotherapy or ambulatory phlebectomies. Patients will be randomised to having either ambulatory phlebectomy (group A) or foam sclerotherapy (group B) following treatment of their saphenous vein.
The re-intervention rates, safety, patient experience as well as the cost effectiveness of each intervention will be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ambulatory phlebectomy of varicose vein tributaries
Procedure: Ambulatory phlebectomy
Injection of foam sclerosant into varicose vein tributaries
Drug: Foam sclerotherapy
Minor surgery to remove varicose vein tributaries
Injection of foam sclerosant into varicose vein tributaries
Re-intervention rate
Re-intervention on varicose vein tributaries during study period
Time frame: 12 months
Generic quality of life score
Quality of life score using the EuroQol's EQ-5D \[0=worse quality of life; 1=best quality of life\]
Time frame: 12 months
Disease-specific quality of life score
Quality of life score using the Aberdeen Varicose Vein Questionnaire (AVVQ) \[0=worse quality of life; 100= best quality of life\]
Time frame: 12 months
Disease specific quality of life score
Quality of life score using the ChronIc Venous Insufficiency Quality of Life Questionnaire (CIVIQ) \[0=worse quality of life; 100=best quality of life\]
Time frame: 12 months
Clinical score
Clinical change using the Venous Clinical Severity Score (VCSS) \[0=least severe disease; 30=most severe disease\]
Time frame: 12 months
Clinical score
Using the Clinical-Etiological-Anatomical-Pathophysiological (CEAP) classification \[0=no varicose veins; 1=telangiectasia; 2= varicose veins; 3=oedema; 4=skin changes; 5=healed ulcer; 6=ulcer\]
Time frame: 12 months
Pain score over the first 10 days
Pain score over the first 10 days using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)
Time frame: 2 weeks
Degree of bruising at 2 weeks
Degree of bruising at 2 weeks using a categorical 0-5 bruising scale (0=no bruising; 5=bruising extending beyond treated segment)
Time frame: 2 weeks
Time to return to normal activities
Time frame: 2 weeks
Plan to share: No
Started Feb 2018 (actual). Primary completion is estimated for May 2025, 87 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.